CoChat

A Switch in Hepatic Cortisol Metabolism across the Spectrum of Non Alcoholic Fatty Liver Disease

Open access

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Abstract

CONTEXT: Non alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome. NAFLD represents a spectrum of liver disease ranging from reversible hepatic steatosis, to non alcoholic steato-hepatitis (NASH) and cirrhosis. The potential role of glucocorticoids (GC) in the pathogenesis of NAFLD is highlighted in patients with GC excess, Cushing's syndrome, who develop central adiposity, insulin resistance and in 20% of cases, NAFLD. Although in most cases of NAFLD, circulating cortisol levels are normal, hepatic cortisol availability is controlled by enzymes that regenerate cortisol (F) from inactive cortisone (E) (11β-hydroxysteroid dehydrogenase type 1, 11β-HSD1), or inactivate cortisol through A-ring metabolism (5α- and 5β-reductase, 5αR and 5βR). OBJECTIVE AND METHODS: In vitro studies defined 11β-HSD1 expression in normal and NASH liver samples. We then characterised hepatic cortisol metabolism in 16 patients with histologically proven NAFLD compared to 32 obese controls using gas chromatographic analysis of 24 hour urine collection and plasma cortisol generation profile following oral cortisone. RESULTS: In patients with steatosis 5αR activity was increased, with a decrease in hepatic 11β-HSD1 activity. Total cortisol metabolites were increased in this group consistent with increased GC production rate. In contrast, in patients with NASH, 11β-HSD1 activity was increased both in comparison to patients with steatosis, and controls. Endorsing these findings, 11β-HSD1 mRNA and immunostaining was markedly increased in NASH patients in peri septal hepatocytes and within CD68 positive macrophages within inflamed cirrhotic septa. CONCLUSION: Patients with hepatic steatosis have increased clearance and decreased hepatic regeneration of cortisol and we propose that this may represent a protective mechanism to decrease local GC availability to preserve hepatic metabolic phenotype. With progression to NASH, increased 11β-HSD1 activity and consequent cortisol regeneration may serve to limit hepatic inflammation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0029531

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 24 hour urine steroid metabolite analysis from patients with steatosis and steatohepatitis compared with obese controls. (A): 5α-reductase activity as depicted by the urinary 5αTHF/THF ratio (mean ± SEM). (B): total 24 Urine 5α-reduced metabolites (mean ± SEM) (Andros: androsterone). (C): total 24 hr Urine F metabolites (mean ± SEM).
Figure 1 24 hour urine steroid metabolite analysis from patients with steatosis and steatohepatitis compared with obese controls. (A): 5α-reductase activity as depicted by the urinary 5αTHF/THF ratio (mean ± SEM). (B): total 24 Urine 5α-reduced metabolites (mean ± SEM) (Andros: androsterone). (C): total 24 hr Urine F metabolites (mean ± SEM).CC BY · PubMed Central
Figure 2 11β-HSD1 activity assessed by: (A) 24 hr urine cortols/cortolones and 5αTHF+THF/THE ratios (mean ± SEM) in patients with steatosis and steatohepatitis compared with controls. (B) Hepatic cortisol generation measured by cortisol generation profiles (mean AUC ± SEM) in patients with steatosis and steatohepatitis compared with controls.
Figure 2 11β-HSD1 activity assessed by: (A) 24 hr urine cortols/cortolones and 5αTHF+THF/THE ratios (mean ± SEM) in patients with steatosis and steatohepatitis compared with controls. (B) Hepatic cortisol generation measured by cortisol generation profiles (mean AUC ± SEM) in patients with steatosis and steatohepatitis compared with controls.CC BY · PubMed Central
Figure 3 Real time PCR mRNA expression data on whole liver samples from 5 normal patients and 5 NASH patients (expressed as arbitrary units ± SEM) for (A)HSD11B1 (11β-HSD 1), (B)SRD5A2 (5α-reductase 2), (C)GRα. ** p<0.01 NASH vs controls; * p<0.05 NASH vs controls.
Figure 3 Real time PCR mRNA expression data on whole liver samples from 5 normal patients and 5 NASH patients (expressed as arbitrary units ± SEM) for (A)HSD11B1 (11β-HSD 1), (B)SRD5A2 (5α-reductase 2), (C)GRα. ** p<0.01 NASH vs controls; * p<0.05 NASH vs controls.CC BY · PubMed Central
Figure 4 Hepatic 11β-HSD 1 immunoreactivity in patients with severe NASH compared to normal controls. There was generally increased staining for 11β-HSD1 throughout the liver parenchyma in (A) NASH samples compared with (B) Normal liver ×20. (C) and (D) Increased staining at the limiting plate in peri-septal areas and strongly staining specific cells within the inflammatory infiltrate in NASH ×10(C) and ×20(D) (E) Confocal microscopy on severe NASH cryosections. Green - 11β-HSD1, red – CD68 IgG macrophage marker, yellow – colocalisation of 11β-HSD1 and CD68 positive macrophages. (F) Western blot analysis of human liver microsomes from normal and NASH livers.
Figure 4 Hepatic 11β-HSD 1 immunoreactivity in patients with severe NASH compared to normal controls. There was generally increased staining for 11β-HSD1 throughout the liver parenchyma in (A) NASH samples compared with (B) Normal liver ×20. (C) and (D) Increased staining at the limiting plate in peri-septal areas and strongly staining specific cells within the inflammatory infiltrate in NASH ×10(C) and ×20(D) (E) Confocal microscopy on severe NASH cryosections. Green - 11β-HSD1, red – CD68 IgG macrophage marker, yellow – colocalisation of 11β-HSD1 and CD68 positive macrophages. (F) Western blot analysis of human liver microsomes from normal and NASH livers.CC BY · PubMed Central
Figure 5 Schematic: Hepatic glucocorticoid metabolism and its modulation in response to disease progression in NAFLD.
Figure 5 Schematic: Hepatic glucocorticoid metabolism and its modulation in response to disease progression in NAFLD.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 46 references

Cited by

Metadata

Authors
Ahmed, A., Rabbitt, E., Brady, T., Brown, C., Guest, P., Bujalska, I. J., Doig, C., Newsome, P. N., Hubscher, S., Elias, E., Adams, D. H., Tomlinson, J. W., & Stewart, P. M.
Affiliations
  • University of Birmingham (GB)
  • University Hospitals Birmingham NHS Foundation Trust (GB)
Corresponding author
Stewart, Paul M.
Venue
PLoS ONE
Published
2012-02-20
Volume
7
Issue
2
Pages
e29531
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2061954662
Cited by
115
References
46
Citations by year
2026: 7 · 2025: 4 · 2024: 10 · 2023: 7 · 2022: 20 · 2021: 10 · 2020: 7 · 2019: 3 · 2018: 8 · 2017: 6 · 2016: 9 · 2015: 9 · 2014: 6 · 2013: 9
FWCI
5.75
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
  • Nottingham Trent University's Institutional Repository (Nottingham Trent Repository) (acceptedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • University of Birmingham Research Portal (University of Birmingham) (submittedVersion, other-oa)
Funders
  • Wellcome Trust (082809, 082809/Z/07/Z)
  • National Institute for Health and Care Research (NF-SI-0508-10356)
  • Medical Research Council
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
Keywords
non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, 11β-hydroxysteroid dehydrogenase type 1, 5α-reductase, 5beta-reductase, glucocorticoids, hepatic steatosis, liver cirrhosis, hepatic macrophages, liver inflammation, metabolic syndrome, Cushing's syndrome
MeSH terms
Adult, Fatty Liver, Humans, Hydrocortisone, Liver, Middle Aged, Models, Biological, Obesity, RNA, Messenger, Gene Expression Regulation, Enzymologic, Case-Control Studies, Disease Progression, 11-beta-Hydroxysteroid Dehydrogenase Type 1, Real-Time Polymerase Chain Reaction, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.